This site is intended for health professionals only

Sanofi-Aventis records net profit


Full year earnings at Sanofi-Aventis are above expectations due to the strong sales of its swine flu vaccine, with the drug maker posting a 10% increase in fourth quarter net profit.

The French company’s net profit rose to euro1.8 billion (£1.43bn) in the fourth quarter of last year, from euro1.63bn a year previously. The firm’s human vaccines business was boosted by a record rise of 64.6% in revenue.

Sanofi-Aventis sold 100 million doses of pandemic vaccines in 2009 and earnings per share on an adjusted basis increased by 13.1% at constant exchange rates, higher than the 11% target set by the firm in October.

Christopher Viehbacher, who became chief executive of the company early last year, said in a statement that: “major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS growth.”

Under Mr Viehbacher’s leadership, Sanofi-Aventis has replaced ageing blockbuster drugs with new treatments and helped the company take on generic competition.

Copyright Press Association 2010


Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine